// App-Quantinova.ai

3410 : Tissue Factor Mediated Activation of Prothrombin Complex Concentrates (PCCs) Is Differently Inhibited by Dabigatran, Rivaroxaban and Apixaban. Potential Clinical Implications

Researchers

Presenter

  • Nasir Sadeghi

Principal Investigators

  • Daniel Kahn

  • Josephine Cunanan

  • Kimberly Bartosiak

  • Job Harenberg

  • Debra Hoppensteadt

Medical Centers

  • Clinical Pharmacology, Ruprecht-Karls-University of Heidelberg, Faculty of Medicine, Mannheim, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Tuberculosis

  • Venous thrombosis

Biomarkers

  • Nucleoside diphosphate kinase A

  • Coagulation Factor III, Tissue Factor

  • Prothrombin

Drug/Treatment

  • Prothrombin complex

  • rivaroxaban

  • Pradax

  • RhThrombin

  • apixaban

  • ocplex

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved